The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

Oxazolidinones having structures represented by structural formula I, preparation methods therefor, and pharmaceutical uses thereof, in particular an application of said compounds and salts or compositions thereof in the treatment of a bacterial infection. In the formula: R.sup.1 is a methyl group, an ethyl group, a propyl group, a cyclopropyl group, or a vinyl group; R.sup.2 is F; and R.sup.3 is F, CH.sub.3, C.sub.2H.sub.5, CF.sub.3, CHF.sub.2, CH.sub.2F, or a cyclopropyl group.

Oxazolidinones having structures represented by structural formula I, preparation methods therefor, and pharmaceutical uses thereof, in particular an application of said compounds and salts or compositions thereof in the treatment of a bacterial infection. In the formula: R.sup.1 is a methyl group, an ethyl group, a propyl group, a cyclopropyl group, or a vinyl group; R.sup.2 is F; and R.sup.3 is F, CH.sub.3, C.sub.2H.sub.5, CF.sub.3, CHF.sub.2, CH.sub.2F, or a cyclopropyl group.

An antimicrobial composition containing a wasp extract, and more particularly, a broad-spectrum antimicrobial composition containing, as an active ingredient, an ethyl acetate fraction recovered by sequential organic solvent fraction of an ethanol extract of Vespa velutina nigrithorax or Vespa simillima simillima Smith. The Vespa velutina nigrithorax extract or the V. simillima simillima Smith extract exhibits excellent broad-spectrum antimicrobial activity against gram-positive bacteria, gram-negative bacterial and fungi, and thus may be used for pharmaceutical compositions, health functional foods, cosmetic compositions, animal feed compositions, additives for food, cosmetics or animal feed, various detergents and various cleansers. In addition, the extract has excellent heat stability, and does not lose its activity even under an acidic condition of pH 2.

A composition and method directed to the treatment of bacterial infections is provided.

A composition and method directed to the treatment of bacterial infections is provided.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 Å (Angstroms) or less.

The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response to an infected individual.

The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.

The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.